IL99261A - שיטות לסינתזת אוליגוניוקלאוטידים בעלי שלישיות קודונים בעלות זוגות קודוניים אקראיים - Google Patents

שיטות לסינתזת אוליגוניוקלאוטידים בעלי שלישיות קודונים בעלות זוגות קודוניים אקראיים

Info

Publication number: IL99261A
Authority: IL; Israel
Prior art keywords: codon; codons; column; synthesis; oligonucleotides
Prior art date: 1990-08-24

Application number

IL9926191A

Other languages

English (en)

Other versions

IL99261A0 (en

Original Assignee

Ixsys Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-08-24

Filing date

1991-08-21

Publication date

1996-09-12

1991-08-21 Application filed by Ixsys Inc filed Critical Ixsys Inc

1992-07-15 Publication of IL99261A0 publication Critical patent/IL99261A0/xx

1996-09-12 Publication of IL99261A publication Critical patent/IL99261A/he

Links

108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 99
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title claims abstract description 69
238000000034 method Methods 0.000 title claims abstract description 53
230000002194 synthesizing effect Effects 0.000 title claims abstract description 18
108020004705 Codon Proteins 0.000 title description 174
238000006243 chemical reaction Methods 0.000 claims abstract description 92
239000000178 monomer Substances 0.000 claims abstract description 89
238000005859 coupling reaction Methods 0.000 claims abstract description 46
230000008878 coupling Effects 0.000 claims abstract description 31
238000010168 coupling process Methods 0.000 claims abstract description 31
238000002156 mixing Methods 0.000 claims abstract description 21
239000003795 chemical substances by application Substances 0.000 claims 1
230000015572 biosynthetic process Effects 0.000 description 73
238000003786 synthesis reaction Methods 0.000 description 73
239000011324 bead Substances 0.000 description 29
150000001413 amino acids Chemical class 0.000 description 20
239000002773 nucleotide Substances 0.000 description 19
125000003729 nucleotide group Chemical group 0.000 description 19
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
239000000203 mixture Substances 0.000 description 15
239000007795 chemical reaction product Substances 0.000 description 11
239000000463 material Substances 0.000 description 10
108090000765 processed proteins & peptides Proteins 0.000 description 8
239000000047 product Substances 0.000 description 8
230000002068 genetic effect Effects 0.000 description 7
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 7
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
239000000725 suspension Substances 0.000 description 6
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
238000002515 oligonucleotide synthesis Methods 0.000 description 5
239000011148 porous material Substances 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
239000011521 glass Substances 0.000 description 4
238000012986 modification Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
241000894007 species Species 0.000 description 4
239000013598 vector Substances 0.000 description 4
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
241000024188 Andala Species 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
230000000692 anti-sense effect Effects 0.000 description 3
229940104302 cytosine Drugs 0.000 description 3
-1 dimethoxytrityl Chemical group 0.000 description 3
238000009826 distribution Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
230000008569 process Effects 0.000 description 3
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
229930024421 Adenine Natural products 0.000 description 2
NSTPXGARCQOSAU-VIFPVBQESA-N N-formyl-L-phenylalanine Chemical compound O=CN[C@H](C(=O)O)CC1=CC=CC=C1 NSTPXGARCQOSAU-VIFPVBQESA-N 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
229960000643 adenine Drugs 0.000 description 2
238000011166 aliquoting Methods 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000002981 blocking agent Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000000539 dimer Substances 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
239000006194 liquid suspension Substances 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
229940113082 thymine Drugs 0.000 description 2
238000013519 translation Methods 0.000 description 2
FMKJUUQOYOHLTF-OWOJBTEDSA-N (e)-4-azaniumylbut-2-enoate Chemical compound NC\C=C\C(O)=O FMKJUUQOYOHLTF-OWOJBTEDSA-N 0.000 description 1
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
108020004485 Nonsense Codon Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical group CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
238000003541 multi-stage reaction Methods 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000001668 nucleic acid synthesis Methods 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
239000002243 precursor Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000000135 prohibitive effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
239000013638 trimer Substances 0.000 description 1
229940035893 uracil Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Saccharide Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

IL9926191A 1990-08-24 1991-08-21 שיטות לסינתזת אוליגוניוקלאוטידים בעלי שלישיות קודונים בעלות זוגות קודוניים אקראיים IL99261A (he)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US57364890A	1990-08-24	1990-08-24

Publications (2)

Publication Number	Publication Date
IL99261A0 IL99261A0 (en)	1992-07-15
IL99261A true IL99261A (he)	1996-09-12

Family

ID=24292837

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9926191A IL99261A (he)	1990-08-24	1991-08-21	שיטות לסינתזת אוליגוניוקלאוטידים בעלי שלישיות קודונים בעלות זוגות קודוניים אקראיים

Country Status (11)

Country	Link
EP (1)	EP0544809B1 (he)
JP (2)	JP3306063B2 (he)
AT (1)	ATE174598T1 (he)
AU (1)	AU8505191A (he)
CA (1)	CA2089362C (he)
DE (1)	DE69130647T2 (he)
IE (1)	IE66123B1 (he)
IL (1)	IL99261A (he)
NZ (1)	NZ239498A (he)
TW (1)	TW217416B (he)
WO (1)	WO1992003461A1 (he)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5498538A (en) *	1990-02-15	1996-03-12	The University Of North Carolina At Chapel Hill	Totally synthetic affinity reagents
US5747334A (en) *	1990-02-15	1998-05-05	The University Of North Carolina At Chapel Hill	Random peptide library
JP2001524926A (ja) *	1991-09-18	2001-12-04	アフィマックステクノロジーズナームロゼフェンノートシャップ	オリゴマーの雑多ライブラリーの集合体を合成する方法
US5639603A (en) *	1991-09-18	1997-06-17	Affymax Technologies N.V.	Synthesizing and screening molecular diversity
PT638089E (pt) *	1992-04-15	2001-09-27	Univ Johns Hopkins	Sintese de coleccoes uteis e diversas de oligonucleotidos
EP0675953B1 (en) *	1992-11-10	2009-01-28	Applied Molecular Evolution, Inc.	Soluble peptides having constrained, secondary conformation in solution and method of making same
US6165778A (en) *	1993-11-02	2000-12-26	Affymax Technologies N.V.	Reaction vessel agitation apparatus
CN1134156A (zh) *	1993-11-02	1996-10-23	阿菲马克斯技术公司	合成和筛选多种分子
US5503805A (en) *	1993-11-02	1996-04-02	Affymax Technologies N.V.	Apparatus and method for parallel coupling reactions
US5587471A (en) *	1994-01-11	1996-12-24	Isis Pharmaceuticals, Inc.	Method of making oligonucleotide libraries
US6395547B1 (en)	1994-02-17	2002-05-28	Maxygen, Inc.	Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6117679A (en)	1994-02-17	2000-09-12	Maxygen, Inc.	Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6165793A (en) *	1996-03-25	2000-12-26	Maxygen, Inc.	Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) *	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
US6995017B1 (en)	1994-02-17	2006-02-07	Maxygen, Inc.	Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6406855B1 (en)	1994-02-17	2002-06-18	Maxygen, Inc.	Methods and compositions for polypeptide engineering
US6335160B1 (en)	1995-02-17	2002-01-01	Maxygen, Inc.	Methods and compositions for polypeptide engineering
US5604097A (en) *	1994-10-13	1997-02-18	Spectragen, Inc.	Methods for sorting polynucleotides using oligonucleotide tags
US5695934A (en) *	1994-10-13	1997-12-09	Lynx Therapeutics, Inc.	Massively parallel sequencing of sorted polynucleotides
US5717085A (en) *	1994-11-23	1998-02-10	Terrapin Technologies, Inc.	Process for preparing codon amidites
US6068829A (en)	1995-09-11	2000-05-30	The Burnham Institute	Method of identifying molecules that home to a selected organ in vivo
US5622699A (en) *	1995-09-11	1997-04-22	La Jolla Cancer Research Foundation	Method of identifying molecules that home to a selected organ in vivo
ATE195181T1 (de) *	1995-09-11	2000-08-15	Jolla Cancer Res Found	Moleküle, die sich in ausgewählten organen oder geweben invivo einfinden und verfahren zu ihrer identifizierung
US6743892B1 (en)	1995-09-11	2004-06-01	La Jolla Cancer Research Foundation	Molecules that home to a selected organ in vivo
US6096548A (en)	1996-03-25	2000-08-01	Maxygen, Inc.	Method for directing evolution of a virus
US6506602B1 (en)	1996-03-25	2003-01-14	Maxygen, Inc.	Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6576239B1 (en)	1996-09-10	2003-06-10	The Burnham Institute	Angiogenic homing molecules and conjugates derived therefrom
US6153410A (en) *	1997-03-25	2000-11-28	California Institute Of Technology	Recombination of polynucleotide sequences using random or defined primers
WO1999023107A1 (en)	1997-10-31	1999-05-14	Maxygen, Incorporated	Modification of virus tropism and host range by viral genome shuffling
DK1036198T3 (da)	1997-12-08	2013-01-02	California Inst Of Techn	Fremgangsmåde til fremstilling af polynukleotid- og polypeptidsekvenser
US7390619B1 (en)	1998-02-11	2008-06-24	Maxygen, Inc.	Optimization of immunomodulatory properties of genetic vaccines
US6541011B2 (en)	1998-02-11	2003-04-01	Maxygen, Inc.	Antigen library immunization
US6232287B1 (en)	1998-03-13	2001-05-15	The Burnham Institute	Molecules that home to various selected organs or tissues
US6365408B1 (en)	1998-06-19	2002-04-02	Maxygen, Inc.	Methods of evolving a polynucleotides by mutagenesis and recombination
CA2362737A1 (en)	1999-03-05	2000-09-08	Maxygen, Inc.	Recombination of insertion modified nucleic acids
CN1109185C (zh) *	1999-06-14	2003-05-21	深圳市怡诺威实业发展有限公司	免拆式汽车发动机保养设备
AU784983B2 (en) *	1999-12-15	2006-08-17	Genentech Inc.	Shotgun scanning, a combinatorial method for mapping functional protein epitopes
WO2001055451A1 (en)	2000-01-28	2001-08-02	Linden Technologies, Inc.	C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support
US7452964B2 (en)	2001-09-07	2008-11-18	Board Of Regents, The University Of Texas System	Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7420030B2 (en)	2000-09-08	2008-09-02	The Board Of Regents Of The University Of Texas System	Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US20040170955A1 (en)	2000-09-08	2004-09-02	Wadih Arap	Human and mouse targeting peptides identified by phage display
EP1489171B1 (en)	2002-03-19	2012-10-31	Fujitsu Limited	Functional molecule and process for producing the same
US7544767B2 (en)	2002-04-05	2009-06-09	Burnham Institute For Medical Research	HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
EP1513879B1 (en)	2002-06-03	2018-08-22	Genentech, Inc.	Synthetic antibody phage libraries
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
CN103145839A (zh)	2005-06-30	2013-06-12	Abbvie公司	Il-12/p40结合蛋白
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
CA2914170C (en)	2006-09-08	2018-10-30	Abbvie Bahamas Ltd.	Interleukin-13 binding proteins
WO2009055656A2 (en)	2007-10-26	2009-04-30	Centocor, Inc.	Vectors, host cells, and methods of production and uses
BRPI0910482A2 (pt)	2008-04-29	2019-09-24	Abbott Lab	imunoglobinas de domínio variável duplo e usos das mesmas
MX2010012142A (es)	2008-05-09	2011-04-05	Abbott Gmbh & Co Kg	Anticuerpos para receptor de productos finales de glucacion avanzada (rage) y usos de los mismos.
BRPI0913366A8 (pt)	2008-06-03	2017-07-11	Abbott Lab	Imunoglobulinas de domínio variável duplo e seus usos
PE20100092A1 (es)	2008-06-03	2010-03-12	Abbott Lab	Inmunoglobulina con dominio variable dual y usos de la misma
NZ603698A (en)	2008-07-08	2014-03-28	Abbvie Inc	Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
SG172855A1 (en)	2009-01-29	2011-08-29	Abbott Lab	Il-1 binding proteins
EP2403531A4 (en)	2009-03-05	2013-02-27	Abbott Lab	IL-17 BINDING PROTEINS
WO2011025964A2 (en)	2009-08-29	2011-03-03	Abbott Laboratories	Therapeutic dll4 binding proteins
KR20120060877A (ko)	2009-09-01	2012-06-12	아보트 러보러터리즈	이원 가변 도메인 면역글로불린 및 이의 용도
AU2010306677B2 (en)	2009-10-15	2013-05-23	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
US8420083B2 (en)	2009-10-31	2013-04-16	Abbvie Inc.	Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
BR112012021941A2 (pt)	2010-03-02	2022-02-01	Abbvie Inc	Proteínas terapêuticas de ligação a dll4
KR101539684B1 (ko)	2010-05-14	2015-07-27	애브비 인코포레이티드	Ｉｌ－１ 결합 단백질
US8735546B2 (en)	2010-08-03	2014-05-27	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
US9505829B2 (en)	2010-08-19	2016-11-29	Zoetis Belgium S.A.	Anti-NGF antibodies and their use
PE20140229A1 (es)	2010-08-26	2014-03-27	Abbvie Inc	Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012088094A2 (en)	2010-12-21	2012-06-28	Abbott Laboratories	Il-1 binding proteins
JP2014533659A (ja)	2011-10-24	2014-12-15	アッヴィ・インコーポレイテッド	スクレロスチンに対するイムノバインダー
AR089529A1 (es)	2011-12-30	2014-08-27	Abbvie Inc	Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
EP2859018B1 (en)	2012-06-06	2021-09-22	Zoetis Services LLC	Caninized anti-ngf antibodies and methods thereof
UY34905A (es)	2012-07-12	2014-01-31	Abbvie Inc	Proteínas de unión a il-1
HUE049693T2 (hu)	2012-08-31	2020-10-28	Immunogen Inc	Diagnosztikai ASSAY-k és készletek a folát receptor 1 kimutatására
KR20180008921A (ko)	2012-11-01	2018-01-24	애브비 인코포레이티드	항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
WO2014100542A1 (en)	2012-12-21	2014-06-26	Abbvie, Inc.	High-throughput antibody humanization
BR112015023239A8 (pt)	2013-03-14	2018-04-17	Abbott Lab	ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
CN113549148B (zh)	2013-03-14	2025-11-21	雅培制药有限公司	Hcv核心脂质结合结构域单克隆抗体
JP2016512241A (ja)	2013-03-14	2016-04-25	アボット・ラボラトリーズＡｂｂｏｔｔＬａｂｏｒａｔｏｒｉｅｓ	改良された抗体検出のためのｈｃｖｎｓ３組換え抗原およびこの突然変異体
CN105324396A (zh)	2013-03-15	2016-02-10	艾伯维公司	针对IL-1β和/或IL-17的双重特异性结合蛋白
GB201406767D0 (en)	2014-04-15	2014-05-28	Cancer Rec Tech Ltd	Humanized anti-Tn-MUC1 antibodies anf their conjugates
WO2016094881A2 (en)	2014-12-11	2016-06-16	Abbvie Inc.	Lrp-8 binding proteins
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3458479B1 (en)	2016-06-08	2020-11-04	AbbVie Inc.	Anti-b7-h3 antibodies and antibody drug conjugates
MX2019005661A (es)	2016-11-16	2019-10-07	Janssen Biotech Inc	Método para tratar la psoriasis con el anticuerpo específico anti-il23.
WO2018098370A1 (en)	2016-11-23	2018-05-31	Immunoah Therapeutics, Inc.	4-1bb binding proteins and uses thereof
EP3565845A4 (en)	2017-01-06	2020-10-07	Biosion, Inc.	ERBB2 ANTIBODIES AND THEIR USES
KR20190113858A (ko)	2017-01-30	2019-10-08	얀센 바이오테크 인코포레이티드	활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
MA47442A (fr)	2017-02-07	2019-12-18	Janssen Biotech Inc	Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
CN117050176A (zh)	2017-07-31	2023-11-14	豪夫迈·罗氏有限公司	基于三维结构的人源化方法
TW201922780A (zh)	2017-09-25	2019-06-16	美商健生生物科技公司	以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EP3694552A1 (en)	2017-10-10	2020-08-19	Tilos Therapeutics, Inc.	Anti-lap antibodies and uses thereof
IL274272B2 (he)	2017-11-06	2025-09-01	Janssen Biotech Inc	שיטה בטוחה ויעילה לטיפול בדלקת מפרקים פסוריאטית עם נוגדן ספציפי אנטי- il23
WO2019160976A1 (en)	2018-02-14	2019-08-22	Viela Bio, Inc.	Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases
CA3092551A1 (en)	2018-03-05	2019-09-12	Janssen Biotech, Inc.	Methods of treating crohn's disease with anti-il23 specific antibody
JP2021517461A (ja)	2018-03-12	2021-07-26	ゾエティス・サービシーズ・エルエルシー	抗ｎｇｆ抗体およびその方法
WO2020016838A2 (en)	2018-07-18	2020-01-23	Janssen Biotech, Inc.	Sustained response predictors after treatment with anti-il23 specific antibody
BR112021005467A2 (pt)	2018-09-24	2021-06-22	Janssen Biotech, Inc.	método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23
EP3863722A2 (en)	2018-10-10	2021-08-18	Tilos Theapeutics, Inc.	Anti-lap antibody variants and uses thereof
MA55149A (fr)	2018-11-20	2021-09-29	Janssen Biotech Inc	Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
US20200197517A1 (en)	2018-12-18	2020-06-25	Janssen Biotech, Inc.	Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
CA3133381A1 (en)	2019-03-14	2020-09-17	Janssen Biotech, Inc.	Manufacturing methods for producing anti-tnf antibody compositions
JP7662529B2 (ja)	2019-03-14	2025-04-15	ヤンセンバイオテツク，インコーポレーテツド	抗ｔｎｆ抗体組成物を産生するための方法
KR20210141990A (ko)	2019-03-14	2021-11-23	얀센 바이오테크 인코포레이티드	항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
KR20210141976A (ko)	2019-03-14	2021-11-23	얀센 바이오테크 인코포레이티드	항-tnf 항체 조성물의 제조 방법
MX2021011328A (es)	2019-03-18	2021-12-10	Janssen Biotech Inc	Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23.
WO2020234834A1 (en)	2019-05-23	2020-11-26	Janssen Biotech, Inc.	Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
MX2021014953A (es)	2019-06-04	2022-01-24	Janssen Biotech Inc	Metodo seguro y eficaz para tratar la artritis psoriasica con el anticuerpo especifico anti-il23.
EP4146273A4 (en)	2020-05-05	2024-07-31	Janssen Biotech, Inc.	METHODS OF TREATING CROHN'S DISEASE USING A SPECIFIC ANTI-IL23 ANTIBODY
KR20230023663A (ko)	2020-05-21	2023-02-17	얀센 바이오테크 인코포레이티드	Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법
EP4178616A4 (en)	2020-07-13	2024-07-24	Janssen Biotech, Inc.	SAFE AND EFFECTIVE METHOD FOR TREATING PSORIATIC ARTHRITIS USING A SPECIFIC ANTI-IL23 ANTIBODY
CA3190230A1 (en)	2020-07-30	2022-02-03	Janssen Biotech, Inc.	Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
UY39610A (es)	2021-01-20	2022-08-31	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr
AU2022238849A1 (en)	2021-03-17	2023-08-31	Receptos Llc	Methods of treating atopic dermatitis with anti il-13 antibodies
AU2022308201A1 (en)	2021-07-09	2024-02-22	Janssen Biotech, Inc.	Manufacturing methods for producing anti-tnf antibody compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4458066A (en) *	1980-02-29	1984-07-03	University Patents, Inc.	Process for preparing polynucleotides
CA2009996A1 (en) *	1989-02-17	1990-08-17	Kathleen S. Cook	Process for making genes encoding random polymers of amino acids

1991
- 1991-08-20 JP JP51511591A patent/JP3306063B2/ja not_active Expired - Fee Related
- 1991-08-20 AT AT91916483T patent/ATE174598T1/de active
- 1991-08-20 AU AU85051/91A patent/AU8505191A/en not_active Abandoned
- 1991-08-20 CA CA002089362A patent/CA2089362C/en not_active Expired - Fee Related
- 1991-08-20 EP EP91916483A patent/EP0544809B1/en not_active Expired - Lifetime
- 1991-08-20 DE DE69130647T patent/DE69130647T2/de not_active Expired - Fee Related
- 1991-08-20 WO PCT/US1991/005939 patent/WO1992003461A1/en not_active Ceased
- 1991-08-21 IL IL9926191A patent/IL99261A/he not_active IP Right Cessation
- 1991-08-22 NZ NZ239498A patent/NZ239498A/en unknown
- 1991-08-23 IE IE299391A patent/IE66123B1/en not_active IP Right Cessation
- 1991-09-26 TW TW080107638A patent/TW217416B/zh active
2001
- 2001-03-15 JP JP2001075101A patent/JP2001299342A/ja active Pending

Also Published As

Publication number	Publication date
DE69130647D1 (de)	1999-01-28
TW217416B (he)	1993-12-11
DE69130647T2 (de)	1999-05-06
JP2001299342A (ja)	2001-10-30
NZ239498A (en)	1993-07-27
EP0544809A4 (en)	1994-08-17
WO1992003461A1 (en)	1992-03-05
CA2089362C (en)	2000-11-21
JP3306063B2 (ja)	2002-07-24
IE66123B1 (en)	1995-12-13
IE912993A1 (en)	1992-02-26
IL99261A0 (en)	1992-07-15
EP0544809A1 (en)	1993-06-09
AU8505191A (en)	1992-03-17
CA2089362A1 (en)	1992-02-25
EP0544809B1 (en)	1998-12-16
JPH06503809A (ja)	1994-04-28
ATE174598T1 (de)	1999-01-15

Legal Events

Date	Code	Title
1997-02-18	FF	Patent granted
1997-06-10	KB	Patent renewed
1998-01-04	KB	Patent renewed
2001-10-31	KB	Patent renewed
2005-11-20	KB	Patent renewed
2010-10-31	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
EP0544809B1 (en)	1998-12-16	Methods of synthesizing oligonucleotides with random codons
US5523388A (en)	1996-06-04	Methods of synthesizing oligonucleotides with random codons
Ike et al.	1983	Solid phase synthesis of polynucleotides. VIII. Synthesis of mixed oligodeoxyribonucleotides by the phosphotriester solid phase method
EP0794001B1 (en)	2000-10-11	Automated system for polynucleotide synthesis and purification
US5175209A (en)	1992-12-29	Porous wafer for segmented synthesis of biopolymers
US6001993A (en)	1999-12-14	Random oligonucleotide libraries and methods of making the same
IE913424A1 (en)	1992-04-08	Surface expression libraries of randomized peptides
CA2749227A1 (en)	2005-01-13	Bead bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries
EP0344177B1 (en)	1994-05-11	Porous wafer for segmented synthesis of biopolymers
WO2000018778A9 (en)	2000-06-08	Synthesis of codon randomized nucleic acids
WO1999051547A2 (en)	1999-10-14	Solid phase synthesis of organic compounds via phosphitylating reagents
Adhin et al.	1990	Complete nucleotide sequence of the group I RNA bacteriophage fr
Khudyakov et al.	2002	Artificial DNA: Methods and applications
Fiers et al.	1969	Studies on the primary structure and the replication mechanism of bacteriophage RNA
US6350595B1 (en)	2002-02-26	Synthesis of polynucleotides having random sequences
Pon	2002	Chemical Synthesis of Oligonucleotides: From Dreams to Automation
WO1997047768A1 (en)	1997-12-18	Method for randomly synthesizing biopolymers
WO2022161450A1 (zh)	2022-08-04	相对反应活性测定方法及寡核苷酸合成反应的设计方法
Ner et al.	1989	A method for introducing random single point deletions in specific DNA target sequences using oligonucleotides
Treiber et al.	1995	A simple method for preparing pools of synthetic oligonucleotides with random point deletions
JP3028814B2 (ja)	2000-04-04	生体高分子の分割合成のための多孔質ウエハー